Drug mechanism‐of‐action discovery through the integration of pharmacological and CRISPR screens

Low success rates during drug development are due, in part, to the difficulty of defining drug mechanism‐of‐action and molecular markers of therapeutic activity. Here, we integrated 199,219 drug sensitivity measurements for 397 unique anti‐cancer drugs with genome‐wide CRISPR loss‐of‐function screen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Syst Biol
Principais autores: Gonçalves, Emanuel, Segura‐Cabrera, Aldo, Pacini, Clare, Picco, Gabriele, Behan, Fiona M, Jaaks, Patricia, Coker, Elizabeth A, van der Meer, Donny, Barthorpe, Andrew, Lightfoot, Howard, Mironenko, Tatiana, Beck, Alexandra, Richardson, Laura, Yang, Wanjuan, Lleshi, Ermira, Hall, James, Tolley, Charlotte, Hall, Caitlin, Mali, Iman, Thomas, Frances, Morris, James, Leach, Andrew R, Lynch, James T, Sidders, Ben, Crafter, Claire, Iorio, Francesco, Fawell, Stephen, Garnett, Mathew J
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7336273/
https://ncbi.nlm.nih.gov/pubmed/32627965
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/msb.20199405
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados